FEELM
FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/
As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disposable category is expected to reach USD2.72 billion, making up over 43% of closed system vaping products.
However, almost all the existing disposable vapes are equipped with cotton coil, which produces relatively large aerosol particles, leading to inefficient deposition of inhaled particles in the lungs, hence low nicotine delivery and satisfaction, as well as harshness in throat. Soft cotton coils are unable to form a stable structure, hence a high leakage rate and unpleasant burnt taste. Uneven heating of cotton coils could also cause a weak flavor consistency, so that vaping experience will fade gradually. Moreover, the selling points of most disposable vapes currently focus on large-mouth puff count, or rather, the huge number of puffs that the disposable will provide.
To address the three pain points, FEELM unveils the world's first ceramic coil disposable pod solution, FEELM Max is to disposable vapes what internal combustion engine is to airplanes, automobiles, ships, submarines, and trains. It aims to provide the next generation of disposable vapes with a stronger, more reliable and efficient atomization “engine”. Just like internal combustion engine, which features high thermal efficiency, light weight, compact size and maneuverability, marking the coming of the second industrial revolution; FEELM Max is expected to lead another ceramic coil revolution in the global vaping industry, since the launch of FEELM Air in January 2022.
This revolutionary vaping solution has largely improved e-liquid utilization by virtue of a cotton-free structure and microporous ceramic coil. Therefore, its puff number is increased by 25% with the same e-liquid volume, compared with traditional cotton coil disposable vapes. Besides, it can provide an unprecedented silky-smooth vaping experience, thanks to the ceramic coil, which generates smaller vaporized aerosol particles, thereby minimizing residue in throat. In contrast to cotton coil disposable vapes, the smoothness is improved also by 30%. This innovation also boasts extraordinary flavor consistency of over 95%, since ceramic coil can guarantee constant vapor production, so as to bring the same strong and great taste till the last puff.
In addition to the three major benefits, FEELM Max also features 46% increased overall harm reduction performance compared with cotton coil vapes, and ultra-low vaping leakage rate of less than 0.03%, empowered by Maze Leakage-proof Technology. The smaller vaporized aerosol particles generated by FEELM ceramic coil tend to deposit more in the lung, bringing greater and faster satisfaction. Meanwhile, FEELM's patented Flavor-Lock technology can bring tailored flavor release with terraced temperature zones.
In early 2022, FEELM Max has been adopted by a specialist vape retailer in the UK. In partnership with FEELM, this retailer has introduced an ultra-slim disposable product equipped with FEELM ceramic coil. Built to be lightweight and compact, this product is designed specifically for smoking cessation. In April, the two partners participated in VApril 2022, the world’s largest vaping awareness campaign to give away disposable vapes to adult smokers seeking to switch in London and Manchester.
At Vaper Expo UK 2022, FEELM has also showcased other industry-leading, pioneering disposable vaping solutions, for example, eco-friendly non-nicotine disposable e-cigarette and anti-dust mouthpiece hygienic e-cigarette. These two have been awarded Red Dot Awards for Product Design 2022 for their green product concepts and avant-garde design. Unlike traditional disposable e-cigarettes made of plastic, the external structure of eco-friendly non-nicotine disposable e-cigarette is composed of recyclable and reusable paper and aluminum foil while anti-dust mouthpiece hygienic e-cigarette features a twist nozzle to prevent the contact of mouthpiece with something unclean, with the product concept originated from lipsticks.
Another award-winning solution displayed at the event is FEELM Air, the world’s thinnest ceramic coil vape pod solution. In collaboration with its global clients, FEELM has demonstrated a series of vaping products of regional leading brands that adopt FEELM Air solution. Moreover, it will announce the 2022 timeline of commercial launch of FEELM Air on a global scale afterwards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
